EuBiologics Expects Cholera Vaccine Sales to Rebound from Q2... Anticipates Expanded Supply in Second Half

Despite a slowdown in oral cholera vaccine (OCV) sales in the first quarter of this year, EuBiologics expects a full-fledged recovery in performance starting from the second quarter of 2026.

EuBiologics announced that its sales for the first quarter of 2026 reached 15,642,560,000 won. Of this, sales from oral cholera vaccines accounted for 15,584,000,000 won.

The company explained that due to the nature of the cholera vaccine business, there are fluctuations in sales between the first and second halves of the year, depending on the procurement schedules of international organizations and seasonal demand changes in Africa. Typically, annual sales are structured with approximately 40% in the first half and about 60% in the second half of the year.

In particular, the company stated that in the first half of last year, emergency demand in response to cholera outbreaks in certain African countries created a strong performance base. Therefore, the company added that this year's first-quarter results should be interpreted in consideration of both the high base effect from the same period last year and differences in supply schedules.

EuBiologics has secured a supply volume of about 60 million doses of cholera vaccine from UNICEF this year. As a result, the company expects to see a recovery in sales from the second quarter and anticipates a greater improvement in earnings in the second half due to expanded supply.

Additionally, the company stated that it is strengthening its supply credibility in the global public vaccine market based on its experience supplying through the World Health Organization's prequalification (WHO PQ) process. Going forward, EuBiologics plans to continue to secure vaccine volumes for preventive campaigns by expanding cooperation with international organizations and national health authorities.

A company representative commented, "Considering the supply contracts already secured and shipment schedules for the second half, we expect a stable supply flow on an annual basis."

This announcement shows that EuBiologics is expecting a recovery in cholera vaccine sales from the second quarter and further earnings growth in the second half, based on its foundation of supplying to international organizations.

This content was produced with the assistance of AI translation services.